“I anticipate that the FDA will next grant Gilead a 2-week combo trial with remdesivir and an anti-inflamatory, since CytoDyn has apparently rejected being involved.”

My hope is that CYDY is still in the running as a possible treatment for COVID19 in combo with remdesivir. Why? Because the solo game is a slow and painful cash burn for CYDY. We’ve had 2 trials approved for over a month and only have 45 total in both trials and I’m sure the cost has been high to even get that far (add the EINDs in there as well). Gilead, on the other hand. has a large budget and can quickly and easily enroll patients. Additionally, they can push for a shorter protocol, which would mean results would return quickly.

At this point in time, CYDY needs $$$$$ to further other indications, pay Samsung, and to uplist. There is no doubt that they’d benefit financially from a combo with remdesivir but they’d also gain more notoriety, bring in bigger investors, doctors, and speed up trial enrollment.

Honestly, I just want the cancer trials to move along and enroll. Those results have been stunning and will bring in revenues that I cannot comprehend at this point (still a few years away). Remdesivir and leronlimab could provide a treatment that would allow those cancer trials to start enrollment again.